Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials

Antzeko izenburuak

• Do the meta-analyses provide a clean bill of health to the use of renin-angiotensin system inhibitors in COVID-19?
  nork: Kow, Chia Siang, et al.
  Argitaratua: (2020)
• The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
  nork: Kow, Chia Siang, et al.
  Argitaratua: (2021)
• Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury
  nork: Kow, Chia Siang, et al.
  Argitaratua: (2020)
• Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
  nork: Kow, Chia Siang, et al.
  Argitaratua: (2020)
• Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis
  nork: Hasan, Syed Shahzad, et al.
  Argitaratua: (2020)